- Home
- TBBB vs MLTX Comparison
TBBB vs MLTX Comparison
Compare TBBB & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBBB
- MLTX
- Stock Information
- Founded
- TBBB 2004
- MLTX 2021
- Country
- TBBB Mexico
- MLTX Switzerland
- Employees
- TBBB N/A
- MLTX N/A
- Industry
- TBBB
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- TBBB
- MLTX Health Care
- Exchange
- TBBB NYSE
- MLTX Nasdaq
- Market Cap
- TBBB 2.9B
- MLTX 2.8B
- IPO Year
- TBBB 2024
- MLTX N/A
- Fundamental
- Price
- TBBB $25.51
- MLTX $51.46
- Analyst Decision
- TBBB Hold
- MLTX Strong Buy
- Analyst Count
- TBBB 6
- MLTX 7
- Target Price
- TBBB $32.67
- MLTX $73.33
- AVG Volume (30 Days)
- TBBB 675.3K
- MLTX 505.9K
- Earning Date
- TBBB 08-11-2025
- MLTX 08-11-2025
- Dividend Yield
- TBBB N/A
- MLTX N/A
- EPS Growth
- TBBB N/A
- MLTX N/A
- EPS
- TBBB 0.16
- MLTX N/A
- Revenue
- TBBB $3,027,881,094.00
- MLTX N/A
- Revenue This Year
- TBBB $34.03
- MLTX N/A
- Revenue Next Year
- TBBB $27.47
- MLTX N/A
- P/E Ratio
- TBBB $156.10
- MLTX N/A
- Revenue Growth
- TBBB 31.48
- MLTX N/A
- 52 Week Low
- TBBB $23.00
- MLTX $31.42
- 52 Week High
- TBBB $35.22
- MLTX $58.26
- Technical
- Relative Strength Index (RSI)
- TBBB N/A
- MLTX 50.00
- Support Level
- TBBB N/A
- MLTX $46.12
- Resistance Level
- TBBB N/A
- MLTX $55.91
- Average True Range (ATR)
- TBBB 0.00
- MLTX 2.39
- MACD
- TBBB 0.00
- MLTX -0.51
- Stochastic Oscillator
- TBBB 0.00
- MLTX 38.13
About TBBB BBB FOODS INC
BBB Foods Inc is a company offering a grocery hard discount model in Mexico. Also that operates through three subsidiaries namely Tiendas Tres B, Tiendas BBB and Desarrolladora Tres BSA de CV of which the main activity of Tiendas Tres B is the sale, purchase, distribution and marketing of all types of products, items and goods, as well as the establishment, and operation of individual stores and distribution centers for the sale of such products.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.